# Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS

> **NCT03362294** · PHASE2 · TERMINATED · sponsor: **Mapi Pharma Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Primary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** GA Depot 40mg once monthly
- **DRUG:** GA Depot 25mg once monthly

## Key facts

- **NCT ID:** NCT03362294
- **Lead sponsor:** Mapi Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-11
- **Primary completion:** 2025-06-20
- **Final completion:** 2025-06-20
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** The study was terminated early as part of a global realignment of Sponsor's clinical development programs. This decision is not related to any safety concerns regarding the IP.
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03362294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03362294, "Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03362294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*